Key Highlights

  • Total revenues were $381.4 million for the third quarter of 2026, down $18.0 million.
  • Full-year total net product Revenue guidance now sits between $1.25 billion and $1.3 billion.
  • Cash, cash equivalents, restricted cash and investments reached $998.7 million.
  • Multiple ascending dose data for SRP-1003 and SRP-1001 are expected in the fourth quarter of 2026.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a company focused on precision genetic medicine for rare diseases, reported its financial results for the third quarter of 2026, with total revenues of $381.4 million for the three months ended September 30, 2026. That compares with $399.4 million in the same period a year earlier. The company also updated its full-year guidance and provided progress updates on its DM1 and FSHD programs, along with new clinical and preclinical data for its existing commercial medicines and pipeline. The release combined financial reporting with these scientific updates, giving a broader view of how the company is allocating its resources across its marketed products and early programs.

Quarterly Revenue and Collaboration Effects

Total revenues fell $18.0 million year over year. The decline was partly offset by a $31.4 million increase in contract Manufacturing revenue linked to commercial ELEVIDYS Supply delivered to Roche, the collaboration partner in the product's commercialization. The mix of revenue sources within the quarter therefore differed from the prior-year period, with manufacturing income supporting the Top Line while other revenue streams moved lower. Because collaboration items can be non-recurring, the headline revenue change does not fully reflect the trend in underlying product sales.

The nine-month figures show a wider gap. Total revenues reached $1,513.4 million for the period ended September 30, 2026, compared with $1,755.3 million a year earlier, a decrease of $241.9 million. That comparison includes $365.0 million of collaboration revenue recognized after Roche declined its option for certain program rights, along with a milestone tied to the first commercial dosing of ELEVIDYS in Japan. Contract manufacturing revenues rose $72.5 million over the nine months, reflecting the same commercial supply arrangement.

Revised Guidance for 2026

The company now expects total net product revenue for 2026 in a range of $1.25 billion to $1.3 billion. The low end of that range was raised by $50.0 million. Management expects ELEVIDYS net product revenue in the fourth quarter to trend in line with the third quarter, consistent with earlier guidance, while noting that gene therapy revenue can vary from period to period. The PMO franchise, which includes EXONDYS 51, VYONDYS 53 and AMONDYS 45, is expected to continue contributing a substantial share of product sales.

On the expense side, the company narrowed its full-year combined non-GAAP Research and Development and selling, general and administrative expense guidance to a range of $800 million to $825 million. The high end of that range was lowered by $25.0 million. The revised ranges reflect a tighter view of operating costs alongside a higher revenue floor, which narrows the spread of possible outcomes for the year as reported. Management also described the revenue floor as a reflection of its commercial execution during the quarter, while the expense range reflects continued focus on Capital allocation.

Pipeline Programs and Clinical Data

Sarepta expects multiple ascending dose data from SRP-1003 and SRP-1001 in the fourth quarter of 2026. These studies are intended to show DMPK knockdown and splicing correction in DM1 and DUX4 knockdown in FSHD. Preclinical data presented at the 2026 Oligonucleotide Therapeutics Society Annual Meeting showed dose-dependent reduction of pathogenic DMPK mRNA in both the nucleus and cytoplasm. The company is also preparing for Phase 3 development in both programs, including the start of clinical supply manufacturing, with the regulatory approach to depend on the data and discussions with the FDA. The company is preparing for both accelerated and traditional approval pathways, which leaves room for different timelines depending on the outcome of those discussions.

Clinical data on ELEVIDYS presented at the 2026 World Muscle Society Annual Congress included patients aged 8 to 12 who were ambulatory at the time of treatment. The company reported durable benefit across two years on measured outcomes compared with a matched external control group. Data from patients treated at ages 2 and 3 showed dystrophin expression 12 weeks after infusion. The company described the evidence base as growing across the ambulatory population, supporting its view of the product's benefit-risk profile, while approaches to managing liver safety risk remain part of the ongoing discussion.

Final Takeaways

The third quarter results show a company managing a revenue base that moved lower year over year, with collaboration and manufacturing income shaping the reported totals. Guidance changes point to a modestly higher product revenue range and tighter expense expectations, while the pipeline timeline places several key data readouts in the fourth quarter. The company reported another quarter of non-GAAP operating profit and positive cash flow, which it linked to its plans to fund late-stage development. Cash and investments rose to $998.7 million from $953.8 million at the end of 2025, . How these items develop in the coming reporting periods will indicate how the company's commercial and pipeline plans align with its financial position.